APA (7th ed.) Citation

CN, J., LD, O., Z, C., AF, M., A, R., IJG, B., . . . AM, S. (2025). DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 66(3), 385. https://doi.org/10.2967/jnumed.124.268695

Chicago Style (17th ed.) Citation

CN, Johnstone, et al. "DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 66, no. 3 (2025): 385. https://doi.org/10.2967/jnumed.124.268695.

MLA (9th ed.) Citation

CN, Johnstone, et al. "DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol. 66, no. 3, 2025, p. 385, https://doi.org/10.2967/jnumed.124.268695.